Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Laboratoire HRA Pharma, 15 rue Béranger, 75003, Paris, France
Pharmacotherapeutic group: Diagnostic agent, test for pituitary function
ATC code: V04CD01
Metopirone inhibits the enzyme responsible for the 11β-hydroxylation stage in the biosynthesis of cortisol and to a lesser extent, aldosterone. The fall in plasma concentration of circulating glucocorticoids stimulates ACTH secretion, via the feedback mechanism which accelerates steroid biosynthesis. As a result, 11-desoxycortisol, the precursor of cortisol, is released into the circulation, metabolised by the liver and excreted in the urine. Unlike cortisol, 11-desoxycortisol does not suppress ACTH secretion and its urinary metabolites may be measured.
These metabolites can easily be determined by measuring urinary 17-hydroxycorticosteroids (17-OHCS) or 17-ketogenic steroids (17-KGS). Metopirone is used as a diagnostic test on the basis of these properties, with plasma 11-desoxycortisol and urinary 17-OHCS measured as an index of pituitary ACTH responsiveness. Metopirone may also suppress biosynthesis of aldosterone, resulting in mild natriuresis.
Metyrapone is rapidly absorbed and eliminated from the plasma. Peak plasma levels usually occur one hour after ingestion of Metopirone; after a dose of 750mg Metopirone, plasma drug levels average 3.7μg/ml. Plasma drug levels decrease to a mean value of 0.5μg/ml 4 hours after dosing. The half-life of elimination of Metopirone from the plasma is 20 to 26 minutes.
Metyrapol, the reduced form of metyrapone, is the main active metabolite. Eight hours after a single oral dose, the ratio of metyrapone to metyrapol in the plasma is 1:1.5. Metyrapol takes about twice as long as metyrapone to be eliminated in the plasma.
Seventy-two hours after a first daily dose of 4.5g Metopirone (750mg every 4 hours), 5.3% of the total dose was excreted in the urine as metyrapone (9.2% in free form and 90.8% conjugated with glucuronic acid), and 38.5% in the form of metyrapol (8.1% in free form and 91.9% conjugated with glucuronic acid).
Pre-clinical data for Metopirone (metyrapone) reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity. Metopirone was not mutagenic with or without metabolic activation in three strains of bacteria. Animal reproduction studies adequate to evaluate teratogenicity and postnatal development have not been conducted with Metopirone. Currently, there are no available non-clinical studies conducted to investigate the genotoxicity, or carcinogenic potential of Metopirone.
Effects in pre-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
